{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-006916","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2022-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:04:09.861729+00:00","generated_at":"2026-06-27T08:55:55.062859+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ImmuCell: Dr. Joseph Crabb resigns as officer/employee; remains as consultant for Re-Tain FDA approvals","bullets":["Dr. Joseph H. Crabb resigned from all employee and officer roles effective Feb 11, 2022.","Crabb engaged as consultant/advisor to President; term through April 30, 2023 or FDA approval date.","Compensation: $70,000 payment due upon receipt of all FDA approvals for Re-Tain (Nisin) if still consulting.","Payment also triggered by change of control or sale/license of Nisin rights while consulting."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-006916","json":"https://secwatch.observer/filing/0001213900-22-006916.json","markdown":"https://secwatch.observer/filing/0001213900-22-006916.md","text":"https://secwatch.observer/filing/0001213900-22-006916.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390022006916/0001213900-22-006916-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390022006916/ea155463-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T08:55:55.062859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21da82a35d","claim":"Dr. Joseph H. Crabb resigned as other_named_officer at IMMUCELL CORP /DE/.","evidence_excerpt":"On February 11, 2022, Dr. Joseph H. Crabb resigned from all positions he held at the Company, including without limitation as an employee and an officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390022006916/0001213900-22-006916-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}